# Centrus Energy Corp ($LEU) — Comprehensive Research **Current Price:** $193.81 (Feb 17, 2026) **Market Cap:** $3.67B **52-Week Range:** $49.40 – $464.25 --- ## 1. What This Company Does ### The Business in One Sentence Centrus is the **only US-owned uranium enrichment company**, transitioning from a pure trading/intermediary model (buying Russian-enriched uranium and reselling it to US utilities) into a **domestic enrichment manufacturer** building its own centrifuge plant — the first new American enrichment capacity in decades. ### History — From Government Monopoly to Bankruptcy to Strategic Asset | Year | Event | |------|-------| | 1950s-1990s | US government operates gaseous diffusion enrichment at Paducah, KY and Portsmouth/Piketon, OH | | 1998 | USEC Inc. created as the privatized successor to DOE's enrichment operations | | 2001 | IPO as USEC Inc. | | 2000s | Gaseous diffusion technology becomes uneconomical vs. centrifuge (10-20x more energy) | | 2013 | Paducah gaseous diffusion plant shut down — Centrus loses domestic production | | 2014 | **Chapter 11 bankruptcy** — restructures as Centrus Energy Corp. Massive debt wiped, equity diluted | | 2014-2023 | Operates as **SWU trader** — buys enriched uranium from Russia/others, resells to US/Japanese utilities | | 2023 | Produces **first US HALEU in 70 years** at Piketon demo cascade | | 2024 | Russia enrichment ban signed (effective Jan 1, 2028). Amir Vexler becomes CEO | | 2025 | Raises $2B war chest. DOE selects Centrus for $900M HALEU award | | 2026 | Begins commercial centrifuge manufacturing. Fluor selected as EPC partner | **Key context:** For the past decade, Centrus has essentially been a **middleman** — buying SWU from foreign suppliers (primarily Russia) and delivering to utilities under long-term contracts. The entire thesis hinges on its transition to **actual domestic production** starting ~2029. ### Leadership **CEO: Amir Vexler** (since Jan 1, 2024, age ~52) - BASc Mechanical Engineering (University of Toronto), MBA (Wilfrid Laurier) - 20+ years nuclear industry: Started at GE nuclear in Toronto, became plant manager - **CEO of Global Nuclear Fuels (GE-Hitachi JV)** 2015-2019 — ran nuclear fuel fabrication - **President/CEO of Orano USA** 2021-2023 — French nuclear giant's US arm - **Assessment:** Strong operational nuclear background. Came from a competitor (Orano, which also received DOE enrichment funding). Knows the fuel cycle, manufacturing, and government contracting. The right profile for an industrial buildout. - **Compensation:** $2.19M (2024). No disclosed insider ownership data available — this is a gap. **CFO: Todd Tinelli** (new in 2025, age ~45) - Previously undisclosed background. Transition costs noted in Q4. - On earnings call, demonstrated strong capital allocation thinking — emphasized not being forced to raise dilutive capital in weak markets. **322 employees** — tiny workforce for a $3.7B company. Hiring aggressively: added 140 in 2025, targeting 150+ net new in 2026. ### How It Makes Money Today **Two segments:** | Segment | 2025 Revenue | % Total | Gross Margin | Description | |---------|-------------|---------|--------------|-------------| | **LEU** | $346.2M | 77% | 32.2% | SWU and uranium sales to utilities | | **Technical Solutions** | $102.5M | 23% | 5.9% | Engineering, HALEU ops contract, DOE work | | **Total** | $448.7M | 100% | 26.2% | | **LEU Segment breakdown:** - **SWU revenue:** $298.7M (+21% YoY) — the core product, enrichment services measured in Separative Work Units - **Uranium revenue:** $47.5M (-54% YoY) — natural uranium component, lumpy **Critical fact: Centrus does NOT currently enrich uranium.** It buys enriched uranium from two foreign suppliers (historically Russia, plus likely Urenco or Orano) and resells. The "enrichment" revenue is a trading spread. Gross margins fluctuate based on contract pricing vs. procurement costs. **Revenue is extremely lumpy.** Quarterly swings are massive: - Q1 2025: $73.1M (45% gross margin) - Q2 2025: $154.5M (35% gross margin) - Q3 2025: $74.9M (-5.7% gross margin — NEGATIVE) - Q4 2025: $146.2M (24% gross margin) This is because deliveries are scheduled irregularly and a single delayed shipment (e.g., Q4 Russian shipment pushed to 2026) swings the quarter. **Technical Solutions** is the government contract business — includes HALEU demo operations at Piketon, engineering services, and national security work. Margins compressed in 2025 because Phase 2 HALEU costs incurred after Nov 2024 aren't earning a fee yet (contract undefinitized). ### What It Sells — Products, Differentiation, Roadmap **Today:** Intermediated enriched uranium (LEU) — commodity product differentiated only by contract relationships and supply reliability. **Tomorrow (2029+):** Domestically enriched LEU and HALEU using proprietary American Centrifuge technology. **HALEU (High-Assay Low-Enriched Uranium):** - Enriched to 5-20% U-235 (vs. standard LEU at 3-5%) - **Required** by ALL advanced reactor/SMR designs: TerraPower Natrium, Oklo Aurora, X-energy Xe-100, NuScale VOYGR - Currently NO commercial HALEU production anywhere in the West - Russia's TENEX is the only commercial producer globally - Centrus has demo'd 1+ metric ton at Piketon; building toward 12 metric tons/year **The roadmap:** | Timeline | Milestone | |----------|-----------| | 2026 | Commercial centrifuge manufacturing begins (Oak Ridge). Fluor mobilizes at Piketon. First certified-for-construction package released. | | 2027-2028 | Centrifuge production ramp. Facility construction at Piketon. Supply chain de-risking. | | 2029 | **First new cascade online** — actual domestic enrichment begins | | 2029-2032 | Progressive cascade additions. HALEU production at 12 MT/year. Approach nth-of-a-kind cost. | | 2032+ | Full commercial scale — target up to 3.5M SWU eventually | ### How It Operates — Capacity, Facilities, Bottlenecks **Two facilities:** 1. **Piketon, Ohio** — the enrichment plant - Former Portsmouth Gaseous Diffusion Plant site (massive DOE-owned facility) - Currently: HALEU demo cascade (16 centrifuges) - Building: Full-scale enrichment plant with commercial centrifuge cascades - New: 150,000 sq ft training/ops/maintenance facility (construction begins 2026) - Fluor is EPC contractor — critical de-risking of construction execution - Creating 300+ new jobs, 50+ already hired in Q4 2025 2. **Oak Ridge, Tennessee** — centrifuge manufacturing - $560M+ investment to transition to high-rate centrifuge production - Launched domestic centrifuge manufacturing Dec 2025 - Creating ~430 jobs - Produces the actual centrifuge machines that go into Piketon **Key bottleneck:** The centrifuge supply chain. Centrus manufactures its own centrifuges (unique among enrichers — others use Urenco's technology under license). This is both a moat and a constraint: - Supply chain must meet **national security requirements** (no foreign dependency on critical components) - First-of-a-kind manufacturing = learning curve, yield issues, slower initial production - Vexler on the call: "Once we achieve supply chain requirements for national security, it allows us to move a little quicker" **The 42-month timeline** from manufacturing start to first cascade operation is the company's baseline. They're working to compress it but won't commit to a specific acceleration. --- ## 2. Where It Sits ### Market Size **Global uranium enrichment market:** - Total global SWU demand: ~55-60 million SWU/year (serving ~440 operating reactors) - SWU spot price: ~$190/SWU (up from ~$60 in 2019 — 24% CAGR per Vexler) - Implied annual market value: **$10-11B+ at current spot prices** **US-specific demand:** - US reactors require ~15-17M SWU/year - Russia exit creates ~6.5M SWU shortfall in domestic supply (per Vexler) - Additional demand from: restarts (TMI 835 MW), uprates (Vistra 433 MW), new pledged reactors **HALEU market (emerging):** - No commercial HALEU market exists yet — it's being created by government policy and SMR demand - SMR commitments: 10-15+ GW announced (Meta 4 GW, Amazon 1.6 GW, Google 2+ GW) - Each GW of SMR capacity requires significant HALEU annually for decades - DOE has allocated $2.7B total for domestic HALEU development - First commercial HALEU demand: late 2020s/early 2030s as SMRs approach operation **Uranium price context:** $89-100+/lb U3O8. Structural deficit — mined supply covers <75% of demand. Growing 28% by 2030, doubling by 2040. ### Competitive Landscape Global enrichment is a **tight oligopoly** — only 5 entities worldwide: | Company | Nationality | Global SWU Capacity | HALEU Capability | US Market Access | |---------|-------------|-------------------|-----------------|-----------------| | **Rosatom/TENEX** | Russia | ~27M SWU (~45%) | Only commercial producer | **Banned** from new US contracts; existing deliveries end Jan 2028 | | **Urenco** | UK/NL/DE | ~18M SWU (~31%) | Exploring, no timeline | Operates 4.9M SWU plant in Eunice, NM (expanding to 5.7M) | | **Orano** | France | ~7.5M SWU (~12%) | DOE award recipient for LEU production | Limited US presence; selected for Oak Ridge LEU production | | **CNNC** | China | ~8M SWU (~12%) | Domestic only | Zero — strategic competitor, not a supplier | | **Centrus** | USA | 0 SWU (demo only) | 1+ MT produced, building to 12 MT/yr | **Only US-owned enricher** | **Plus one new entrant:** | **General Matter** | USA (startup) | 0 | DOE $900M award | Planning Paducah facility — years behind Centrus | **Competitive dynamics — enricher by enricher:** **Rosatom:** The elephant leaving the room. 45% of global capacity, cheapest producer. The Russia ban is the single biggest structural tailwind for every other enricher. However, waivers exist for committed deliveries through 2027, and Centrus itself still relies on Russian supply for current contracts (received waivers for 2026-2027 deliveries). The real supply shock hits 2028+. **Urenco:** The most direct competitor in the US market. Already operates the only commercial enrichment plant on US soil (Eunice, NM), but it's European-owned with European technology. Expanding by 15% (800K SWU). They could pursue HALEU but haven't committed. Key distinction: Urenco uses its own centrifuge tech across multiple global facilities — proven, scaled, but **not American-owned**, which matters for national security. **Orano:** French state-backed. Received DOE funding for LEU production at Oak Ridge. Vexler previously ran Orano USA — he knows their capabilities and limitations intimately. Orano is a fuel cycle player (mining, enrichment, reprocessing) but their enrichment capacity is smaller and mostly serving the French/European fleet. **General Matter:** The wild card. A startup that also received $900M from DOE for HALEU production, planning a facility at Paducah. They are **years behind Centrus** — no demo production, no centrifuge manufacturing, no EPC partner announced. The DOE is hedging its bets by funding multiple players, but General Matter's timeline is likely 2032+ at earliest. **CNNC:** China's enricher. Not a factor in Western markets but worth noting they're expanding rapidly for domestic consumption and potentially Belt & Road nuclear exports. ### Defensibility — What's Hard to Replicate **Strong moats:** 1. **Centrifuge technology IP** — Centrus owns the American Centrifuge design outright. This is classified national security technology. You can't buy it, license it, or reverse-engineer it without decades of R&D and government clearance. 2. **DOE relationship** — Decades of history (including the messy USEC years). DOE has invested $900M+ specifically in Centrus. NNSA sole-sourced certain enrichment activities to Centrus. This is a deep institutional relationship. 3. **HALEU first-mover** — Only entity to have produced HALEU in the US. 1+ metric ton delivered to DOE. Building to 12 MT/year. General Matter is years behind. 4. **Piketon facility** — Massive existing DOE site with infrastructure, security clearances, and regulatory approvals already in place. 5. **National security status** — "Only production-ready option for the national security establishment" per NNSA. This is a designation that's nearly impossible to replicate. 6. **Time-to-market** — In a supply-constrained market with 42-month build timelines, being first matters enormously. Each year of delay for competitors is a year of monopoly-like pricing power. **Weaker moats:** 1. **Current trading business** — Pure intermediary. Anyone with supply contracts could do this. The margin depends on locked-in procurement prices vs. rising spot. 2. **Customer relationships** — Utility contracts are ultimately about price and reliability. If Urenco or Orano offers better terms, Centrus loses. 3. **Technology risk** — The American Centrifuge has never operated at commercial scale. If it underperforms (lower throughput, higher maintenance, reliability issues), the cost advantage evaporates. ### Customer/Partner Ecosystem **Customers:** - US and Japanese nuclear utilities (60% US, 18% Japan revenue) - DOE/NNSA for national security enrichment - Future: SMR developers (TerraPower, Oklo, X-energy) for HALEU - Future: Hyperscalers (already in discussions for prepayment/offtake agreements) **Key partners:** - **Fluor** — EPC contractor for Piketon expansion (best-in-class nuclear construction) - **KHMP and POSCO International** (Korean) — MOU for foreign direct investment (low-cost capital) - **DOE/DOD** — funding partners and demand source **Lock-in:** Once SMRs are built using HALEU fuel from Centrus, switching enrichment suppliers is extremely difficult — fuel qualification takes years, and with limited HALEU sources, customers are effectively locked in for reactor lifetimes (40-60 years). This creates **recurring revenue with near-zero churn** — the holy grail of business models, if it materializes. --- ## 3. What The Market Is Paying For ### Current Valuation | Metric | Value | Percentile (Historical) | |--------|-------|------------------------| | P/E (TTM) | 46.9x | 90th — near all-time high | | P/S (TTM) | 8.2x | 100th — **literal all-time high** | | EV/EBITDA | 31.0x | 90th | | EV/FCF | 115.6x | 90th | | EV/Revenue | 8.1x | Near highs | For context, this was a 3-10x P/E stock as recently as 2022-2023. The market has dramatically re-rated $LEU from "nuclear fuel trader" to "strategic infrastructure monopoly." ### What The Price Assumes At $193.81 / $3.67B market cap, the market is pricing: 1. **Successful transition from trader to manufacturer** — the centrifuge buildout works, is on time (~2029), and reaches economical production costs 2. **HALEU monopoly premium** — Centrus captures the vast majority of early US HALEU demand 3. **SWU price escalation continues** — the 24% CAGR in SWU pricing persists or accelerates post-Russia ban 4. **Backlog converts** — the $2.3B contingent LEU backlog becomes firm (contingencies are removed as Centrus demonstrates production capability) 5. **Government support continues** — DOE/NNSA funding flows, waivers are maintained, political support holds ### Where Assumptions Could Be Wrong — Bull Direction - **SWU pricing could spike** much higher than expected post-2028 Russia ban — there's simply not enough non-Russian capacity being built to fill the gap. If SWU prices go to $250-300+, Centrus's margins on its backlog explode upward. - **HALEU demand could front-load** if SMR developers need fuel for testing, demo units, and first cores earlier than expected. Centrus has the only supply. - **National security premium** — Congress could mandate US-enriched uranium for defense purposes, creating a captive demand pool at cost-plus margins. - **Hyperscaler prepayments** — If hyperscalers fund Centrus directly (like they're doing with SMR developers), it reduces dilution risk and validates the thesis. - **Faster buildout** — If the 42-month timeline compresses to 30-36 months, revenue/earnings step up earlier. ### Where Assumptions Could Be Wrong — Bear Direction - **Execution failure** — The American Centrifuge has never operated commercially. If it has reliability problems, throughput issues, or cost overruns, the entire thesis collapses. This is not a theoretical risk — USEC's gaseous diffusion was economically unviable, and the prior centrifuge program was troubled enough to contribute to bankruptcy. - **Dilution** — Already ~20% diluted in 2025 ($534M ATM + convertible). If the buildout costs more or takes longer, more dilution is coming. The $350-500M capital spend guided for 2026 alone is enormous relative to $31M FCF. - **Russia sanctions loosened** — A geopolitical thaw or Trump administration deal could ease or delay the Russia enrichment ban. Even extending waivers would reduce urgency for domestic capacity. - **Urenco/Orano capture HALEU** — If European enrichers develop HALEU capability faster than expected, Centrus's monopoly premium erodes. Urenco has the centrifuge technology and scale; they just haven't prioritized HALEU. - **SMR delays** — If advanced reactors are pushed from 2030-2032 to 2035+, HALEU demand doesn't materialize when expected, and Centrus has built capacity with no customers. - **Nth-of-a-kind costs disappoint** — Management says they'll reach competitive unit costs "way before 3.5M SWU" but won't disclose the actual cost. If production costs exceed SWU market prices, the plant destroys value. ### Capital Structure **As of Dec 31, 2025:** | Item | Amount | |------|--------| | Unrestricted cash | $2.0B | | Total debt | $1.21B (includes convertible notes) | | Net cash | $743M (cash exceeds debt) | | Equity | $765M | | D/E ratio | 1.59x | | Shares outstanding | ~19.7M (Class A) | **How it's being funded:** 1. **ATM equity** — $534M raised in 2025 (~20% dilution). Average price $269/share on Nov program. 2. **Convertible notes** — Aug 2025 oversubscribed issuance. 2.25% coupon. ~2.8M potentially dilutive shares. 3. **DOE awards** — $900M HALEU enrichment award (milestone-based, NOT debt or equity). Could exceed $1B with options. 4. **Operating cash flow** — $51M in 2025. Modest relative to capital needs. 5. **Future:** National security funding, hyperscaler prepayments, foreign direct investment (Korean MOU). **The dilution math matters.** From ~15.2M shares (Q4 2024) to ~19.7M shares (Q4 2025) = **~30% dilution in one year**. If the stock drops and they need more capital, dilution accelerates at worse prices. The $2B war chest provides runway but was expensive — raised at average prices well above current $194. **Positive framing:** The $900M DOE award is effectively free capital (procurement, not debt/equity). If national security funding and hyperscaler prepayments materialize, the remaining buildout can be funded without further equity dilution. Todd Tinelli emphasized they don't want to raise in a down market. ### Revenue Trajectory — Where They Are vs. Where They Need To Be **Current state:** - $449M revenue (flat YoY), mostly intermediary trading - $78M net income, $31M FCF - Margins depend on procurement cost (buying from Russia/others) vs. selling price **2026 guidance:** $425-475M revenue (flat). This is still the legacy trading business. **The gap:** For the current $3.7B valuation to make sense at the current ~47x P/E, the market needs to see: - Revenue ramp from domestic production starting 2029-2030 - $2.3B contingent LEU backlog converting to firm (this alone is ~5x current annual revenue, spread over years) - HALEU revenue at premium pricing (no benchmark yet, but enrichment to 20% vs 5% requires 5-10x more SWU per unit of fuel) - Technical Solutions segment growing as national security contracts scale **Back-of-envelope target state (2032+):** - If Centrus reaches 1M SWU/year at $190/SWU = $190M enrichment revenue - Plus HALEU at premium = additional $50-100M+ - Plus technical solutions = $100M+ - Plus legacy trading = declining but $100M+ - Total potential: $400-600M+ revenue at 30-40% gross margins on domestic production vs. current 26% The market is paying for the 2030s version of this company today. That's either prescient or premature depending on execution. --- ## 4. What Could Change ### Risks — Rated by Severity | Risk | Severity | Reasoning | |------|----------|-----------| | **Centrifuge technology fails at scale** | **CRITICAL** | Never commercially proven. If reliability, throughput, or cost disappoint, the entire thesis unwinds. This is the binary risk. | | **Execution delay** (>42 months) | **HIGH** | Supply chain, national security requirements, first-of-a-kind manufacturing all create delay risk. Every year of delay = more dilution, deferred revenue, and competitor catch-up. | | **Russia sanctions relaxed** | **HIGH** | Geopolitical risk. Trump admin has shown willingness to negotiate with Russia. Even waiver extensions reduce urgency for domestic capacity. | | **Further dilution** | **HIGH** | $350-500M capex in 2026 alone. If costs overrun or markets weaken, more shares get printed at worse prices. 30% diluted already in 2025. | | **SMR timeline delays** | **MODERATE** | HALEU demand depends on advanced reactors. No SMR will operate before ~2030 at best. Delays to 2035+ are very plausible given nuclear project history. | | **Competitor HALEU capacity** | **MODERATE** | General Matter has $900M DOE award. Urenco could pivot. Orano is receiving funding. Monopoly may become oligopoly by 2032. | | **SWU price collapse** | **LOW** | Structural supply deficit makes this unlikely near-term. Would require massive Russian supply re-entry or demand destruction. | | **Political/regulatory** | **LOW-MOD** | Nuclear has bipartisan support currently. NRC ADVANCE Act streamlines licensing. Risk is a shift in political winds or NRC delays. | ### Catalysts **Positive:** | Catalyst | Impact | Timing | |----------|--------|--------| | First commercial centrifuge produced | Validates manufacturing capability | H2 2026 | | Contingent backlog conversion to firm | De-risks $2.3B revenue pipeline | 2026-2027 | | DOE $900M contract finalized | Confirms HALEU funding terms | H1 2026 | | Russia enrichment ban takes effect | Domestic supply urgency peaks | Jan 1, 2028 | | First cascade operational | Actual domestic enrichment begins | 2029 | | Hyperscaler prepayment/offtake agreement | Validates HALEU demand, low-cost capital | 2026-2027 | | NNSA sole-source contract signed | National security revenue stream | 2026 | | SWU spot price spikes post-Russia ban | Margin expansion on backlog | 2028+ | **Negative:** | Catalyst | Impact | Timing | |----------|--------|--------| | Manufacturing delay announced | Timeline pushback = multiple compression | Any time | | Russia sanctions eased/waivers extended | Thesis deferred | 2026-2027 | | Urenco announces HALEU program | Monopoly premium erodes | 2026-2028 | | Further equity raise at lower prices | Dilution accelerates | 2026-2027 | | SMR program cancellation or major delay | HALEU demand deferred | 2027+ | ### Bull Case — Steelmanned Centrus is a **once-in-a-generation infrastructure monopoly** being created by geopolitics, government policy, and secular energy demand. The Russia ban (Jan 2028) removes 45% of global enrichment supply from Western markets permanently. There is not enough capacity being built to fill this gap. SWU prices, already up 24% CAGR since 2019, will spike significantly — potentially doubling. Centrus's $2.3B backlog was likely contracted at prices below where the market is going, meaning massive margin expansion is possible. On HALEU, Centrus has the field to itself. General Matter is years behind. European enrichers haven't committed. Every SMR that gets built — and hyperscalers have committed 10-15+ GW — needs HALEU fuel for its 40-60 year lifetime. This is a **recurring revenue stream with zero substitution risk** because once a reactor is licensed for a specific fuel, switching is a multi-year regulatory process. The DOE's $900M+ award, NNSA sole-source designation, and Korean FDI interest all confirm that the US government views Centrus as a strategic national asset. This is the kind of government backing that de-risks execution significantly — Centrus won't be allowed to fail. With $2B cash and the DOE award, the buildout is funded without further dilution. If Vexler executes on the 42-month timeline and reaches nth-of-a-kind costs, Centrus becomes a **high-margin domestic enricher** in a market with structural supply deficits, captive government demand, and locked-in commercial customers. A $10B+ market cap (3x from here) is conservative in that scenario. ### Bear Case — Steelmanned Centrus is a **$450M/year trading company with no production** being valued at $3.7B on the promise of technology that has never worked commercially. The American Centrifuge program has a troubled history — it was a factor in USEC's bankruptcy. The 42-month timeline to first cascade is optimistic for a first-of-a-kind industrial buildout. Nuclear projects have a nearly universal track record of delays and cost overruns (see: Vogtle, Olkiluoto, Hinkley Point). The company diluted shareholders 30% in 2025 and will spend $350-500M in 2026 capex against $31M of free cash flow. The current trading business is flat-lining at ~$450M revenue with lumpy, unpredictable margins. Every quarter where a Russian shipment is delayed reminds you that the current business depends entirely on the country whose ban is supposed to be the catalyst. The $2.3B "contingent" backlog has significant contingencies — these aren't firm orders. If Centrus can't demonstrate production capability on time, customers can walk. And competitors are being funded: General Matter got $900M, Orano got funding for Oak Ridge, Urenco is expanding. The "monopoly" may not last. Most importantly, HALEU demand depends on SMRs that don't exist yet. No SMR will operate commercially before 2030 at the absolute earliest, and nuclear timelines always slip. If SMRs are a 2035+ story, Centrus has built expensive HALEU capacity with no customers for years. At 47x P/E and P/S at a literal all-time high, the stock prices in perfect execution of a plan that hasn't started. Any stumble — technology, timeline, political — and this is a $100 stock or worse. ### Key Timeline | Date | Milestone | Significance | |------|-----------|-------------| | 1998 | USEC Inc. created | Government enrichment privatized | | 2014 | Chapter 11 → Centrus Energy | Restructured, debt eliminated | | 2023 | First US HALEU produced | Demo cascade proves technology | | Jan 2024 | Amir Vexler becomes CEO | Operational leader for buildout | | 2025 | $2B raised, DOE $900M award, NYSE uplisting | Funded for buildout | | Dec 2025 | Commercial centrifuge manufacturing begins | Supply chain activated | | Feb 2026 | Fluor selected as EPC partner | Construction de-risked | | H2 2026 | First commercial centrifuge completed | Manufacturing proof point | | Jan 2028 | Russia enrichment ban takes effect | Supply shock begins | | 2029 | First cascade online | Actual domestic enrichment starts | | 2029-2032 | Progressive capacity additions | Ramp to 12 MT/yr HALEU + LEU | | 2030-2035 | First SMRs operational | HALEU demand materializes | | 2032+ | Target 3.5M SWU at nth-of-a-kind cost | Full-scale domestic enricher | --- ## 5. Assessment ### What I Know - Centrus is the only US-owned enricher and first US HALEU producer - The Russia ban creates a structural supply gap starting 2028 - $2B cash + $900M DOE award funds the near-term buildout - 47x P/E prices in significant execution success - The stock is down 58% from its $464 high — significant sentiment reset - SWU pricing has a strong structural tailwind (24% CAGR since 2019) ### What I Assume - The American Centrifuge technology works at commercial scale (unproven) - The 42-month timeline is approximately achievable (nuclear projects typically run late) - Russia sanctions hold through the current administration (geopolitical bet) - SMRs will eventually be built, creating HALEU demand (consensus view but timing uncertain) ### What I Don't Know - Actual centrifuge unit economics (classified/undisclosed) - CEO and insider ownership percentages (not found in public data) - Whether the $2.3B contingent backlog will actually convert - Specific terms of the convertible note (conversion price, maturity) - Whether hyperscaler prepayment discussions will close ### The Core Question Is Centrus a **strategic infrastructure monopoly at the beginning of a multi-decade tailwind**, or a **pre-revenue industrial project trading at a premium on promises**? The answer depends almost entirely on execution of the Piketon buildout. Everything else — Russia ban, SMR demand, SWU pricing — is secondary to whether the centrifuges actually work and produce at economical costs. At $194 (down 58% from highs), much of the euphoria has been wrung out. But at 47x earnings on a flat-revenue trading business with $350-500M in annual capex ahead, the stock is still priced for success. **Position sizing should reflect the binary nature of this bet.** If the buildout works, this is a $400+ stock again. If it stumbles, $100 is possible. The 42-month clock starts now. --- ## Sources - $LEU Q4/FY2025 earnings call transcript (Feb 11, 2026) - FMP financial data (annual/quarterly statements, valuation, ownership) - Perplexity research: leadership backgrounds, competitive landscape, capital structure - Existing vault research: [[themes/_nuclear-energy]], [[stocks/LEU/LEU]] - ANS.org, PR Newswire, Zacks, MarketBeat for earnings/operational updates